Table 2.
Factors associated with mortality in subjects with COVID-19-associated mucormycosis (CAM)
| Variable | Odds ratio (95% CI) | P value |
|---|---|---|
| Age, in years | 1.018 (0.993–1.043) | 0.17 |
| CAM reported from India | 0.492 (0.207–1.170) | 0.11 |
| Risk factor for mucormycosis | ||
| Diabetes mellitus | Reference category | |
| COVID-19 only | 0.953 (0.472–1.923) | 0.89 |
| Hematological malignancy or organ transplant | 0.620 (0.095–4.042) | 0.62 |
| Others | 3.374 (0.746–15.271) | 0.11 |
| ICU admission or MV for COVID-19 | 2.274 (1.183–4.373) | 0.014 |
| Glucocorticoid usage | 0.832 (0.380–1.823) | 0.65 |
| Days to the diagnosis of mucormycosis from COVID-19 | 0.997 (0.978–1.017) | 0.79 |
| Site of involvement | ||
| Rhino-orbital mucormycosis | Reference category | |
| Rhino-orbito-cerebral mucormycosis | 1.447 (0.332–6.300) | 0.62 |
| Pulmonary | 3.221 (1.009–10.728) | 0.048 |
| Others | 3.299 (1.631–6.671) | 0.001 |
| Surgical therapy for CAM | 0.940 (0.451–1.959) | 0.87 |
| Combination medical therapy for CAM | 0.363 (0.181–0.729) | 0.004 |
CAM COVID-19-associated mucormycosis, CI confidence interval, COVID-19 coronavirus disease, ICU intensive care unit, MV mechanical ventilation